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Since 2006 ERT is available in Europe and numerous stud-
ies were reported both in infantile and in juvenile - adult patients 
that demonstrated variable efficacy (1, 2). We have followed in-
fants treated with ERT either early in the first year or later. In 
one child with onset at birth, diagnosed in the third day of life 
we observed an excellent long-term clinical response on severe 
bradycardia and reduction of left ventricular mass index in car-
diomyopathy (3) while in another child where the therapy was 
post-pond no such response was observed: in this second case 
a large connective tissue replacement was present in the biopsy 
after ERT. In juvenile and late onset cases a large experience 
was collected by the Italian group of GSDII (4) and will be soon 
reported in full. Beside the clinical follow-up we also did a re-
peated second biopsy after ERT in two cases after 6 months in 
a 17 year old juvenile case and after 36 months of ERT in a 63 
year ventilator dependent woman and we observed less degree 
of vacuolization in muscle fibers. We documented that ERT im-
proves muscle fiber trophism and decreases PAS positivity, as 
well as the extensive muscle autophagic vacuolization. We did 
observe that ERT is effective in both infantile and late-onset GS-
DII cases, but at a different extent. To explain the difference of 
ERT in late onset cases we suppose that fiber sarcolemmal mem-
brane  compartimentalization  around  autophagosomes  might 
contribute to the different response in infants and adults; in fact 
we previously reported (5) that there is a greater degree of fiber 
sarcolemmal membranes around vacuoles in muscle fibers of 
late-onset GSDII, versus classical infantile Pompe patients. This 
protective mechanism may influence the delivery of ERT in adult 
cases. Furthermore a high antibody titer against recombinant en-
zyme has been observed (1, 6) both in infants and in adults and 
might influence ERT efficacy. Finally body composition (I.e fat 
and connective tissue) and the different mannose receptor den-
sity in various tissues (heart, skeletal muscle, diaphragm) has to 
be considered. ERT is the first treatment developed for GSDII, 
but it needs further refinements. Several trials are in fact explor-
ing new avenues of treatment (chaperons, new compounds with 
different affinity for mannose receptor, immunotherapy, etc.). 
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ated with one of the following criteria: PaCO2 > 45 mmHg; 
episodes of desaturation during a night-time monitoring (SaO2 
<88% for 5 consecutive minutes); MIP < 60 cm H2O or a FVC 
< 50% of predicted values in patients with progressive neu-
romuscular diseases. According to the international consensus 
additional physiological criteria are: PaO2 in the waking state 
and during clinical stability < 60 mmHg, vital capacity (VC) 
< 20-30% predicted or < 1.0 L, maximum pressure inspiratory 
(MIP) < 30 cm H2O, unlike the CV in the transition from up-
right to supine position > 25%; tachypnoea: respiratory rate > 
27 breaths / min. Noninvasive mechanical ventilation helps pa-
tients to breathe when the muscle becomes deficient. It inter-
acts with the patient having an adequate alveolar ventilation, 
improving  oxygenation  and  reducing  hypercapnia.  Patients 
treated with noninvasive mechanical ventilation have reduced 
dyspnea and hypersomnia and improved sleep; also fatigue 
disappeared in most patients. 
In patients with Pompe disease progressive muscle weak-
ness renders ineffective the mechanism of cough, with stagnation 
of secretions. This causes atelectasias, pneumonia, acute respira-
tory failure with need for frequent hospitalization. airway clear-
ance techniques can facilitate the mobilization and removal of 
secretions that clutter the airways. The use of airway clearance 
techniques, including assisted coughing techniques, both manual 
and mechanical, and secretion mobilization techniques, is strong-
ly recommended. These techniques should always be included in 
the treatment of chronic NMD patients. Chest percussion and vi-
bration can help to mobilize peripheral airway secretions but they 
are not substitutes for coughing and, unlike for assisted coughing, 
have never been shown to decrease pulmonary morbidity and mor-
tality. Cough can be assisted by manual and mechanical means. 
There are a wide variety of techniques available from which to 
choose, ranging from manual techniques to mechanically assisted 
maneuvers. The possibility of using devices for assisted coughing 
should be individually evaluated. 
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